Table 3.

Univariate and multivariate analyses of recurrence after extirpative procedure.

	Univariate analysis			Multivariate analysis
Characteristics	HR	95% CI	p	HR	95% CI	p
Age at procedure (years)
<30	1.39	(0.46–4.18)	0.56	0.28	(0.10–1.29)	0.07
30–45	1.33	(0.52–3.37)	0.55	1.84	(0.36–1.98)	0.77
>45	1.00	–	–	1.00	–	–
Ethnicity
Black	0.63	(0.23–1.71)	0.34
Caucasian	0.70	(0.14–3.62)	0.66
Hispanic	–	–	–
Other	1.00	(0.28–3.53)	1.00
Current smoker	0.49	(0.22–1.11)	0.09
Intravenous drug use	0.49	(0.10–2.29)	0.34
Parity (multiparous vs. nulliparous)	1.04	(0.09–11.70)	0.97
Ever had an STI	1.74	(0.80–3.77)	0.16
Current hormone contraceptive use	2.74	(0.41–18.30)	0.28
Missed appointments
Rarely (0–3)	1.00	–	–
Frequently (3+)	1.49	(0.78–2.86)	0.21
Current HAART use	0.84	(0.38–1.84)	0.67
Time to first follow-up
≤6 months	1.00	–	–
>6 months	0.81	(0.36–1.81)	0.61
Procedure type
LEEP	3.26	(1.52–7.00)	0.005	3.38	(1.55–7.39)	0.02
Conization	1.00	–	–	1.00	–	–
Margin status (endo-and ectocervical)
Both positive	3.85	(1.22–12.27)	0.03	6.12	(1.90–19.73)	0.03
Either positive	2.07	(0.94–4.60)	0.09	2.58	(0.16–6.16)	0.12
Both negative	1.00	–	–	1.00	–	–
CD4 count at time of procedure (±8 weeks)
≤200 cells/µL	1.47	(0.44–4.95)	0.53
201–500 cells/µL	0.74	(0.30–1.86)	0.52
>500 cells/µL	1.00	–	–
Viral load at time of procedure (±8 weeks)
Undetectable	–	–	–	––		–
Detectable –20,000 copies/mL	0.56	(0.21–1.50)	0.28	0.62	(0.26–1.48)	0.43
>20,000 copies/mL	1.89	(0.79–4.52)	0.18	6.32	(2.22–17.94)	0.01

All significant p-values (p<0.05) were italicized.